Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$48.42 USD

48.42
1,273,772

-0.25 (-0.51%)

Updated May 20, 2024 04:00 PM ET

After-Market: $48.45 +0.03 (0.06%) 7:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 24% (190 out of 249)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Sanofi (SNY) Stock Continues to Gain on Key Drug Approvals

After declining in 2016, share price of French pharma giant Sanofi (SNY) has picked up in 2017.

    Arpita Dutt headshot

    Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data

    Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.

      Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline

      We issued an updated research report on Alnylam Pharmaceuticals, Inc. (ALNY) on May 23, 2017.

        Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis

        Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has approved their pipeline candidate sarilumab to be marketed under the trade name of Kevzara.

          Sanofi Wins Favorable CHMP Opinion for Biosimilar Humalog

          Sanofi (SNY) recently announced that the CHMP has given a positive opinion, recommending marketing approval to a biosimilar version of Humalog (insulin lispro).

            Arpita Dutt headshot

            Merck vs. Sanofi: Which Stock is a Better Pick Post Q1 Earnings?

            Merck (MRK) and Sanofi (SNY) are both Zacks Rank #2 (Buy) stocks. Which company looks better-positioned for the remainder of the year?

              Arpita Dutt headshot

              Pharma Stock Roundup: J&J's Pharma Pipeline Update, Shire's HAE Data & More

              This week, industry bellwether J&J (JNJ) provided a look at its pharma pipeline while Shire was up on HAE data.

                Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q1

                Immune Design Corp. (IMDZ) reported first-quarter 2017 loss of 50 cents per share, narrower than the Zacks Consensus Estimate of a loss of 62 cents and also a year-ago loss of 61 cents.

                  Kevin Cook headshot

                  Bull of the Day: Regeneron (REGN)

                  Shares launched 25% recently as Kevzara and the launch of Dupixent are expected to reignite sales growth

                    AstraZeneca (AZN) Shows Strength: Stock Moves 9.2% Higher

                    AstraZeneca PLC (AZN) shares rose above 9% in the last trading session.

                      Impax (IPXL) Q1 Earnings Miss, Stock Up on Cost Savings Plan

                      Impax Laboratories Inc. (IPXL) posted first-quarter 2017 adjusted earnings of 11 cents per share, missing the Zacks Consensus Estimate of 12 cents. Earnings were down 74.4% from 43 cents in the year-ago period

                        Alnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y

                        Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.25 per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of $1.22 and the year-ago loss of $1.21.

                          Keryx (KERX) Q1 Loss Wider than Expected, Revenues Beat

                          Keryx Biopharmaceuticals Inc. (KERX) reported first-quarter 2017 loss of 21 cents per share, narrower than the year-ago loss of 39 cents

                            BioMarin (BMRN) Posts Earnings in Q1, Sales Top, Stock Up

                            BioMarin Pharmaceutical Inc. (BMRN) reported earnings of 3 cents per share in the first quarter of 2017.

                              Regeneron (REGN) Q1 Earnings Miss, Revenues Beat Estimates

                              Regeneron Pharmaceuticals, Inc. (REGN) reported first-quarter 2017 results wherein earnings missed estimates while revenues beat expectations.

                                VIVUS (VVUS) Loss Narrower than Expected, Revenues Up Y/Y

                                VIVUS Inc. (VVUS) reported a loss of 1 cent per share in the first quarter of 2017, which was narrower than a loss of 12 cents in the year-ago period as well as the Zacks Consensus Estimate of a loss of 13 cents

                                  Arpita Dutt headshot

                                  6 FDA Events to Watch Out for in May 2017

                                  Here is a look at a few important regulatory events scheduled for the month of May including the FDA's decision regarding the label expansion of Merck's (MRK) Keytruda.

                                    Regeneron (REGN) to Post Q1 Earnings: What's in the Cards?

                                    Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release first-quarter 2017 results on May 4, before the opening bell.

                                      Sanofi (SNY) Q1 Earnings Top, Sales Rise Y/Y, Shares Up

                                      Sanofi (SNY) reported first-quarter 2017 earnings of 75 cents per American depositary share, which beat the Zacks Consensus Estimate of 73 cents by 2.7%.

                                        Vertex (VRTX) Q1 Earnings Top, CF Products Sales Strong

                                        Vertex Pharmaceuticals Incorporated (VRTX) reported first-quarter 2017 earnings per share of 13 cents (including the impact of stock-based compensation expense), which beat the Zacks Consensus Estimate of 4 cents.

                                          Arpita Dutt headshot

                                          Pharma Stock Roundup: Lilly, Bristol-Myers, Novartis Q1 Earnings & More

                                          Several major pharma companies including Lilly (LLY) and Bristol-Myers reported Q1 results this week.

                                            Amgen (AMGN) Q1 Earnings Top, Sales Miss, Shares Decline

                                            Biotech major Amgen Inc. (AMGN) reported first-quarter 2017 earnings of $3.15 per share, beating the Zacks Consensus Estimate of $3.00 by 5% .

                                              Lilly (LLY) Tops Q1 Earnings, Misses Sales, Shares Down

                                              Eli Lilly and Company (LLY) reported first-quarter 2017 adjusted earnings per share of 98 cents, which beat the Zacks Consensus Estimate of 96 cents by 2.1%.

                                                Arpita Dutt headshot

                                                Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL

                                                Key highlights from the pharma sector include J&J's (JNJ) first quarter results and a CRL for Lilly's RA drug.

                                                  Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?

                                                  Eli Lilly and Company (LLY) will report first-quarter 2017 results on Apr 25, before the market opens.